Previous 10 | Next 10 |
Never underestimate the appeal of stupidity said with conviction. " - Kevin Focke Today, we revisit Esperion Therapeutics ( ESPR ) we had as an option play of the week in mid-November to Biotech Forum members exclusively via a simple covered call strategy. The shares shot up from $4...
ANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American Diabetes Association 80 th Scientific Sessions. According to the American Diabetes Assoc...
ANN ARBOR, Mich., June 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today confirms it has received notice that the Institute of Clinical and Economic Review (ICER) plans to assess new non-statin medicines for hypercholesterolemia in the U.S., including the clinical cost effectivenes...
ANN ARBOR, Mich., June 08, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11, 2020,...
Esperion ( ESPR +2.8% ) announces that NEXLIZET (bempedoic acid and ezetimibe) tablets, the first approved oral, non-statin LDL-Cholesterol (LDL-C) lowering combination medicine is now available in U.S. pharmacies. More news on: Esperion Therapeutics, Inc., Healthca...
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with Minimal to No Paperwork Requirements for Health Care Providers ...
It’s no secret the global pandemic is creating unprecedented market volatility. Companies racing for a vaccine like Moderna and Inovio have seen their market valuations soar and then fall with every new headline. However, a number of companies focused on developing innovative new drug ...
ANN ARBOR, Mich., May 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare Conference 2020 on Tuesday, June 2, 2020, at 1...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with this Read more ...
Despite most of the world putting their attention towards COVID-19, cardiovascular disease is still the world-leading healthcare crisis. Esperion Therapeutics ( ESPR ) is attempting to alleviate that enduring problem with its affordable, convenient, oral, once-daily, non-statin, LDL-C medicine...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...